“…2,6 Although insulin glargine also has a modification at the carboxy-terminal end of the B chain, it undergoes biotransformation in human serum to metabolites M1 and M2 and the M1 metabolite binds to the Roche assay. 6,7 In contrast, the antibodies in the Advia Centaur immunoassay are directed against a different region of the insulin molecule. Therefore, it recognises insulin aspart, lispro, detemir and glargine, but not glulisine, because of the additional amino acid substitution at the amino-terminal end of the B chain.…”